Premaitha Health PLC (LON:NIPT)‘s stock had its “corporate” rating restated by research analysts at FinnCap in a research note issued on Monday. They currently have a GBX 20 ($0.25) price objective on the stock. FinnCap’s price objective would suggest a potential upside of 138.81% from the company’s current price.

Shares of Premaitha Health PLC (LON:NIPT) opened at 8.38 on Monday. Premaitha Health PLC has a one year low of GBX 6.50 and a one year high of GBX 21.50. The company’s market capitalization is GBX 19.11 million. The stock has a 50 day moving average price of GBX 9.31 and a 200 day moving average price of GBX 9.42.

Premaitha Health PLC Company Profile

Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques. The Company’s techniques are used for pre-natal screening (NIPT) and other clinical applications in the early detection, monitoring and treatment of disease.

Receive News & Stock Ratings for Premaitha Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premaitha Health PLC and related stocks with our FREE daily email newsletter.